BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...treat males ages 13 to 22 with Fragile X syndrome. The selective extrasynaptic agonist of GABRD...
...RBX2660 is an enema formulation of intestinal microbes derived from healthy donor fecal material. Targets GABRD...
BioCentury | Aug 14, 2019
Company News

Patient access, antisense oligo key to Angelman deal for Ultragenyx

...of the UBE3A gene, and gaboxadol (OV101) from Ovid Therapeutics Inc. (NASDAQ:OVID). Gaboxadol is a GABRD...
...A receptor that's dampened by loss of UBE3A (see "Doing More with Less" ). Targets: GABRD...
BioCentury | Jun 28, 2019
Product Development

How small companies can leverage big changes in rare diseases

...randomized controlled trials in Angelman’s has given the company some tough lessons. Ovid’s candidate, the GABRD...
...NYSE:TAK), Tokyo, Japan Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA, Petach Tikva, Israel Targets GABRD...
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

...to enroll the first patient next quarter; top-line data for the selective extrasynaptic agonist of GABRD...
...by mid-2020 (see "Doing More With Less" ). Targets: CTGF - Connective tissue growth factor; GABRD...
BioCentury | Aug 18, 2018
Product Development

Doing more with less

...slate of potential outcomes. The Phase II STARS trial tested the GABA A receptor δ (GABRD...
...concentrations of GABA escape the synaptic cleft and bind to extrasynaptic GABA A receptor δ (GABRD...
...to neuronal hyperexcitability. Gaboxadol (OV101) replaces the effects of missing GABA by selectively activating extrasynaptic GABRD...
BioCentury | Aug 10, 2018
Clinical News

Ovid's Angelman syndrome candidate misses behavior, sleep and gait endpoints in Phase II

...discuss next steps with regulatory agencies. The selective extrasynaptic agonist of GABA A receptor δ (GABRD...
...OV101) Business: Neurology Molecular target: GABA A receptor δ (GABRD) Description: Selective extrasynaptic agonist of GABRD...
...mPOMA-G) scale Status: Phase II data Milestone: Start Phase II extension (4Q18) Chris Lieu gaboxadol (OV101) Ovid Therapeutics Inc. GABA A receptor delta (GABRD) Neurology...
BioCentury | Aug 6, 2018
Clinical News

Ovid falls on Phase II data for Angelman syndrome candidate

...discuss next steps with regulatory agencies. The selective extrasynaptic agonist of GABA A receptor δ (GABRD...
...has exclusive, worldwide rights to the candidate from H. Lundbeck A/S (CSE:LUN). Chris Lieu gaboxadol (OV101) Ovid Therapeutics Inc. GABA A receptor delta (GABRD) Neurology...
BioCentury | Dec 22, 2017
Strategy

Ovid spreads its wings

...Ovid obtained OV101, a small molecule agonist of GABA A receptors that contain the δ-subunit GABRD...
...normal levels of tonic inhibition. During said OV101 selectively agonizes extrasynaptic GABA receptors because the GABRD...
...Silver Spring, Md. Targets CYP46A1 (CH24H) - Cytochrome P450 family 46 subfamily A polypeptide 1 GABRD...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...in adolescents with either Angelman syndrome or fragile X syndrome. Gaboxadol is a selective extrasynaptic GABA A receptor delta (GABRD)...
BioCentury | May 6, 2017
Financial News

Ovid dips in first trading day

...II testing to treat Angelman syndrome. The small molecule is a selective, extrasynaptic agonist of GABA A receptor delta (GABRD)...
...A polypeptide 1 ( CYP46A1 ; CH24H) (see BioCentury, Jan. 20, 2017) . Becky Simon gaboxadol OV101 Ovid Therapeutics Inc. GABA A receptor delta (GABRD)...
Items per page:
1 - 10 of 15